Literature DB >> 15905010

Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy.

Keisuke Kobayashi1, Eiji Shimizu, Kenji Hashimoto, Makoto Mitsumori, Kaori Koike, Naoe Okamura, Hiroki Koizumi, Shintaro Ohgake, Daisuke Matsuzawa, Lin Zhang, Michiko Nakazato, Masaomi Iyo.   

Abstract

Little is known about biological predictors of treatment response in panic disorder. Our previous studies show that the brain-derived neurotrophic factor (BDNF) may play a role in the pathophysiology of major depressive disorders and eating disorders. Assuming that BDNF may be implicated in the putative common etiologies of depression and anxiety, the authors examined serum BDNF levels of the patients with panic disorder, and its correlation with therapeutic response to group cognitive behavioral therapy (CBT). Group CBT (10 consecutive 1 h weekly sessions) was administered to the patients with panic disorder after consulting the panic outpatient special service. Before treatment, serum concentrations of BDNF and total cholesterol were measured. After treatment, we defined response to therapy as a 40% reduction from baseline on Panic Disorder Severity Scale (PDSS) score as described by [Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 283, 2529-2536]. There were 26 good responders and 16 poor responders. 31 age- and sex-matched healthy normal control subjects were also recruited in this study. The serum BDNF levels of the patients with poor response (25.9 ng/ml [S.D. 8.7]) were significantly lower than those of the patients with good response (33.7 ng/ml [S.D. 7.5]). However, there were no significant differences in both groups of the patients, compared to the normal controls (29.1 ng/ml [S.D. 7.1]). No significant differences of other variables including total cholesterol levels before treatment were detected between good responders and poor responders. These results suggested that BDNF might contribute to therapeutic response of panic disorder. A potential link between an increased risk of secondary depression and BDNF remains to be investigated in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905010     DOI: 10.1016/j.pnpbp.2005.04.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  20 in total

Review 1.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

2.  Serum BDNF levels before treatment predict SSRI response in depression.

Authors:  Owen M Wolkowitz; Jessica Wolf; Wendy Shelly; Rebecca Rosser; Heather M Burke; George K Lerner; Victor I Reus; J Craig Nelson; Elissa S Epel; Synthia H Mellon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-07-03       Impact factor: 5.067

Review 3.  Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants.

Authors:  Florian Duclot; Mohamed Kabbaj
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

Review 4.  [The development of depression: the role of brain-derived neurotrophic factor].

Authors:  H Stuke; R Hellweg; F Bermpohl
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

Review 5.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

6.  The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders.

Authors:  Michael L Sulkowski; Daniel A Geller; Adam B Lewin; Tanya K Murphy; Andrew Mittelman; Ashley Brown; Eric A Storch
Journal:  Curr Psychiatry Rev       Date:  2014

Review 7.  Cognitive enhancers for anxiety disorders.

Authors:  Stefan G Hofmann; Jasper A J Smits; Anu Asnaani; Cassidy A Gutner; Michael W Otto
Journal:  Pharmacol Biochem Behav       Date:  2010-12-04       Impact factor: 3.533

8.  Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation.

Authors:  Undine E Lang; Malek Bajbouj; Juergen Gallinat; Rainer Hellweg
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

9.  BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects.

Authors:  Alessandra Minelli; Roberta Zanardini; Cristian Bonvicini; Riccardo Sartori; Laura Pedrini; Massimo Gennarelli; Luisella Bocchio-Chiavetto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-03       Impact factor: 5.270

Review 10.  Exploring exercise as an avenue for the treatment of anxiety disorders.

Authors:  Lindsey B DeBoer; Mark B Powers; Angela C Utschig; Michael W Otto; Jasper A J Smits
Journal:  Expert Rev Neurother       Date:  2012-08       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.